Start the conversation
4/3/15: Pfizer Inc. (NYSE: PFE) is ceasing vaccine sales operations in China after the Chinese government failed to renew an import license for one of its products, a move that the company said will cause a shortage of the treatment in China. The vaccine protects toddlers against pneumococcal disease that can lead to pneumonia and other infections. “Based on a careful assessment of this situation, we have decided to cease our Vaccines commercial operations in China at this time, effective immediately,” a statement from Pfizer said. The vaccine is Pfizer’s No. 2-selling franchise globally, behind the Lyrica pain drug. Global sales of Prevenar-branded products reached $4.5 billion in 2014, up 12%, up from a year earlier.